Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: Although Parkinson disease with dementia (PDD) and dementia with Lewy bodies (DLB) show a wide clinical and neuropathologic overlap, they are differentiated according to the order and latency of cognitive and motor symptom appearance. Whether both are distinct disease entities is an ongoing controversy. Therefore, we directly compared patients with DLB and PDD with multitracer PET.
Methods: PET with 18fluorodopa (FDOPA), N-11C-methyl-4-piperidyl acetate (MP4A), and 18fluorodeoxyglucose (FDG) was performed in 8 patients with PDD, 6 patients with DLB, and 9 patients with PD without dementia vs age-matched controls. Data were analyzed with voxel-based statistical parametric mapping and region of interest–based statistics.
Results: We found a reduced FDOPA uptake in the striatum and in limbic and associative prefrontal areas in all patient groups. Patients with PDD and patients with DLB showed a severe MP4A and FDG binding reduction in the neocortex with increasing signal diminution from frontal to occipital regions. Significant differences between PDD and DLB were not found in any of the radioligands used. Patients with PD without dementia had a mild cholinergic deficit and no FDG reductions vs controls.
Conclusions: Patients with dementia with Lewy bodies and Parkinson disease dementia share the same dopaminergic and cholinergic deficit profile in the brain and seem to represent 2 sides of the same coin in a continuum of Lewy body diseases. Cholinergic deficits seem to be crucial for the development of dementia in addition to motor symptoms. The spatial congruence of cholinergic deficits and energy hypometabolism argues for cortical deafferentation due to the degeneration of projection fibers from the basal forebrain.
Glossary
- AADC=
- aromatic acid decarboxylase;
- AChE=
- acetylcholine esterase;
- CMRglc=
- cerebral metabolic rate of glucose;
- DLB=
- dementia with Lewy bodies;
- FDG=
- 18fluorodeoxyglucose;
- FDOPA=
- 18fluorodopa;
- LB=
- Lewy bodies;
- LN=
- Lewy neurites;
- MMSE=
- Mini-Mental State Examination;
- MP4A=
- N-11C-methyl-4-piperidyl acetate;
- nbM=
- basal nucleus of Meynert;
- PD=
- Parkinson disease;
- PDD=
- Parkinson disease with dementia;
- PiB=
- Pittsburgh compound B;
- ROI=
- region of interest;
- SPM=
- statistical parametric mapping.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Differences in Age-related Retinal and Cortical Atrophy Rates in Multiple Sclerosis
Prof. Massimo Filippi and Dr. Paolo Preziosa
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Views & Reviews
DLB and PDD boundary issuesDiagnosis, treatment, molecular pathology, and biomarkersC. F. Lippa, J. E. Duda, M. Grossman et al.Neurology, March 12, 2007 -
Articles
Mapping of brain acetylcholinesterase alterations in Lewy body disease by PETH. Shimada, S. Hirano, H. Shinotoh et al.Neurology, May 27, 2009 -
Article
Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body diseaseJulia Shirvan, Nathan Clement, Rong Ye et al.Neurology, June 26, 2019 -
Articles
Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodiesMona K. Beyer, Jan P. Larsen, Dag Aarsland et al.Neurology, August 20, 2007